Latest Headlines

Latest Headlines

VaxInnate reaps $53M for flu jab trials on BARDA contract extension

The U.S. Department of Health and Human Services apparently likes what it's seen from a 5-year contract with VaxInnate. Its Biomedical Advanced Research and Development Authority (BARDA) has extended the contract's base period with the flu vaccine maker, a move that allows for the use of $53 million.

VaxInnate bird flu shot flies into Phase I

VaxInnate's VAX161, the company's vaccine in development to protect against a bird flu pandemic, has moved into Phase I trials.

Interview: VaxInnate plots its future following HHS contract

"VaxInnate: We're fast, cheap and easy," jokes CSO Alan Shaw (pictured, left). And that's just what the HHS likes about the company. Last month the agency granted the Cranbury,...

Interview: Novavax's CEO discusses HHS flu vaccine funding

Earlier this week, the HHS doubled down on new vaccine technology. The government granted Maryland-based Novavax a contract worth up to $179.1 million, while Cranbury, NJ's VaxInnate picked up a

Novavax, VaxInnate win $215M to develop better pandemic vaccines

The feds drive to whip up a bigger, faster supply of flu vaccine to fight pandemics has triggered a pair of new contracts initially totaling $215 million for Novavax and VaxInnate. Novavax shares

VaxInnate nabs $30M in fourth venture round

The Wellcome Trust has signed on as a new investor of VaxInnate, leading a $30 million Series D for the vaccine developer as it pursues a more efficient approach to the field. New Leaf Venture

Universal flu vax works in early-stage trial

VaxInnate's universal flu vaccine has produced positive results in an early stage trial at the University of Texas at Galveston. Researchers there said that VaxInnate's M2e universal vaccine